Develops AI-powered software for breast imaging analytics. Offers Volpara Analytics to optimize breast cancer screening operations. Now — the numbers.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
We do not hold enough financial data on this company to point to a strength.
The stock sits at $0.74. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, earnings execution, the revenue breakdown.